科华生物：公司2025年半年度已实现营业收入7.94亿元

Core Viewpoint - The company reported a revenue of 794 million yuan for the first half of 2025, indicating a stable financial performance [1] Group 1 - The company responded to investor inquiries on September 30, confirming its revenue figures [1] - The revenue of 794 million yuan was disclosed in the company's semi-annual report for 2025 [1] - The company stated that its stock is not subject to delisting risk warnings as per current regulations [1]